Sep 2026
Abstract B139: Targeting wild-type IDH1 creates a PARP inhibitor vulnerability in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies, with an estimated 5-year overall survival rate of around 13%. Current treatment options provide limited therapeutic benefit. The clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in PDAC is largely restricted to the smal...
Parsa Rezvani, Mehrdad Zarei, Sami O. Abul-Khoudoud et al.
· Cancer Research · 0 citations